BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22482234)

  • 1. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New hope in metastatic melanoma treatment?].
    Guillot B
    Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
    [No Abstract]   [Full Text] [Related]  

  • 3. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib. Value unclear in metastatic melanoma.
    Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib in melanoma.
    Shaw HM; Nathan PD
    Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
    Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
    J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
    [No Abstract]   [Full Text] [Related]  

  • 9. Aflibercept, ipilimumab, and vemurafenib.
    Hussar DA; Au AY
    J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic therapy for metastatic melanoma in 2012: dawn of a new era.
    Bhatia S; Thompson JA
    J Natl Compr Canc Netw; 2012 Mar; 10(3):403-12. PubMed ID: 22393198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
    Dean E; Lorigan P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New paradigms and metaphors in cutaneous melanoma treatment].
    Piérard GE; Nizet JL; Humbert P
    Rev Med Liege; 2016 Dec; 71(12):562-566. PubMed ID: 28387097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Malignant melanoma].
    Schmid-Wendtner M; Wendtner CM
    Dtsch Med Wochenschr; 2012 Dec; 137(49):2548-50. PubMed ID: 23188634
    [No Abstract]   [Full Text] [Related]  

  • 15. New targeted therapies in melanoma.
    Kudchadkar RR; Gonzalez R; Lewis K
    Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New treatment options for metastatic melanoma].
    Tietze JK; Berking C
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
    Degen A; Völker B; Kapp A; Gutzmer R
    Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Kiyota N; Ejima Y; Nakajima K; Nishigori C
    Eur J Dermatol; 2017 Apr; 27(2):177-178. PubMed ID: 27873735
    [No Abstract]   [Full Text] [Related]  

  • 19. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
    Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
    J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
    [No Abstract]   [Full Text] [Related]  

  • 20. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.